284 related articles for article (PubMed ID: 29720397)
1. Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors.
Grouthier V; Lebrun-Vignes B; Glazer AM; Touraine P; Funck-Brentano C; Pariente A; Courtillot C; Bachelot A; Roden DM; Moslehi JJ; Salem JE
Heart; 2018 Nov; 104(22):1859-1863. PubMed ID: 29720397
[TBL] [Abstract][Full Text] [Related]
2. Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study.
Salem JE; Bretagne M; Lebrun-Vignes B; Waintraub X; Gandjbakhch E; Hidden-Lucet F; Gougis P; Bachelot A; Funck-Brentano C;
Arch Cardiovasc Dis; 2019 Nov; 112(11):699-712. PubMed ID: 31477476
[TBL] [Abstract][Full Text] [Related]
3. CredibleMeds.org: What does it offer?
Woosley RL; Black K; Heise CW; Romero K
Trends Cardiovasc Med; 2018 Feb; 28(2):94-99. PubMed ID: 28801207
[TBL] [Abstract][Full Text] [Related]
4. Citalopram induced torsade de pointes, a rare life threatening side effect.
Kanjanauthai S; Kanluen T; Chareonthaitawee P
Int J Cardiol; 2008 Dec; 131(1):e33-4. PubMed ID: 17919753
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Understanding of QTc Prolongation and Gender as Risk Factors for Torsade de Pointes.
Johannesen L; Garnett C; Luo M; Targum S; Sørensen JS; Mehrotra N
Clin Pharmacol Ther; 2018 Feb; 103(2):304-309. PubMed ID: 29219167
[TBL] [Abstract][Full Text] [Related]
6. Long-term proarrhythmic pharmacotherapy among patients with congenital long QT syndrome and risk of arrhythmia and mortality.
Weeke PE; Kellemann JS; Jespersen CB; Theilade J; Kanters JK; Hansen MS; Christiansen M; Marstrand P; Gislason GH; Torp-Pedersen C; Bundgaard H; Jensen HK; Tfelt-Hansen J
Eur Heart J; 2019 Oct; 40(37):3110-3117. PubMed ID: 31079148
[TBL] [Abstract][Full Text] [Related]
7. Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system.
Ali Z; Ismail M; Khan F; Sajid H
Expert Opin Drug Saf; 2021 Jan; 20(1):101-107. PubMed ID: 33141610
[No Abstract] [Full Text] [Related]
8. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
9. Safely Administering Potential QTc Prolonging Therapy Across a Large Health Care System in the COVID-19 Era.
Saleh M; Gabriels J; Chang D; Fishbein J; Qiu M; Mountantonakis SE; Epstein LM;
Circ Arrhythm Electrophysiol; 2020 Nov; 13(11):e008937. PubMed ID: 33003964
[TBL] [Abstract][Full Text] [Related]
10. Cardiac arrhythmia considerations of hormone cancer therapies.
Barber M; Nguyen LS; Wassermann J; Spano JP; Funck-Brentano C; Salem JE
Cardiovasc Res; 2019 Apr; 115(5):878-894. PubMed ID: 30698686
[TBL] [Abstract][Full Text] [Related]
11. Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes.
Abi-Gerges N; Philp K; Pollard C; Wakefield I; Hammond TG; Valentin JP
Fundam Clin Pharmacol; 2004 Apr; 18(2):139-51. PubMed ID: 15066127
[TBL] [Abstract][Full Text] [Related]
12. QT variability during initial exposure to sotalol: experience based on a large electronic medical record.
Weeke P; Delaney J; Mosley JD; Wells Q; Van Driest S; Norris K; Kucera G; Stubblefield T; Roden DM
Europace; 2013 Dec; 15(12):1791-7. PubMed ID: 23787903
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of Microvolt T-Wave Alternans in Patients With Long QT Syndrome and Its Association With Torsade de Pointes.
Takasugi N; Goto H; Takasugi M; Verrier RL; Kuwahara T; Kubota T; Toyoshi H; Nakashima T; Kawasaki M; Nishigaki K; Minatoguchi S
Circ Arrhythm Electrophysiol; 2016 Feb; 9(2):e003206. PubMed ID: 26839386
[TBL] [Abstract][Full Text] [Related]
14. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations.
Carlsson L; Abrahamsson C; Andersson B; Duker G; Schiller-Linhardt G
Cardiovasc Res; 1993 Dec; 27(12):2186-93. PubMed ID: 8313427
[TBL] [Abstract][Full Text] [Related]
15. Estimates of population-based incidence of malignant arrhythmias associated with medication use-a narrative review.
Huang Y; Alsabbagh MW
Fundam Clin Pharmacol; 2020 Aug; 34(4):418-432. PubMed ID: 32538484
[TBL] [Abstract][Full Text] [Related]
16. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.
Hii JT; Wyse DG; Gillis AM; Duff HJ; Solylo MA; Mitchell LB
Circulation; 1992 Nov; 86(5):1376-82. PubMed ID: 1423949
[TBL] [Abstract][Full Text] [Related]
17. Long QT syndrome caused by noncardiac drugs.
Viskin S; Justo D; Halkin A; Zeltser D
Prog Cardiovasc Dis; 2003; 45(5):415-27. PubMed ID: 12704598
[TBL] [Abstract][Full Text] [Related]
18. Measurement of J-T
Goto A; Hagiwara-Nagasawa M; Kambayashi R; Chiba K; Izumi-Nakaseko H; Naito AT; Kanda Y; Sugiyama A
Cardiovasc Toxicol; 2019 Aug; 19(4):357-364. PubMed ID: 30712162
[TBL] [Abstract][Full Text] [Related]
19. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
Howell A; Howell SJ; Clarke R; Anderson E
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
[TBL] [Abstract][Full Text] [Related]
20. Association of Oral Contraceptives With Drug-Induced QT Interval Prolongation in Healthy Nonmenopausal Women.
Salem JE; Dureau P; Bachelot A; Germain M; Voiriot P; Lebourgeois B; Trégouët DA; Hulot JS; Funck-Brentano C
JAMA Cardiol; 2018 Sep; 3(9):877-882. PubMed ID: 30073300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
